NASDAQ:OASM Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free OASM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.02▼$0.0250-Day Range$1.30▼$1.6252-Week Range$0.94▼$5.70VolumeN/AAverage Volume98,414 shsMarket Capitalization$1.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Oasmia Pharmaceutical AB (publ) alerts: Email Address Ad Schaeffer’s ResearchJust Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.Yes! Show Me This Strategy About Oasmia Pharmaceutical AB (publ)Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Read More Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him OASM Stock News HeadlinesMarch 23, 2024 | morningstar.comLipigon Pharmaceuticals AB LPGOMarch 6, 2024 | gurufocus.comLSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call TranscriptApril 25, 2024 | The TradingPub (Ad)At first glance, this chart looks like nonsense…We can isolate the most bullish dates to buy Netflix each and every year… That’s why one former hedge fund manager calls these dates… “Hotspot Dates”March 6, 2024 | gurufocus.comOasmia Pharmaceutical AB (publ) - Special Call TranscriptFebruary 8, 2024 | finance.yahoo.comResurs Holding AB (publ) (RESURS.ST)January 6, 2024 | morningstar.comQuiaPEG Pharmaceuticals Holding AB QUIANovember 29, 2023 | investing.comNewbury Pharmaceuticals AB (NEWBRY)September 14, 2023 | investing.comLipigon Pharmaceuticals AB (LPGO)April 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.August 25, 2023 | investing.comSpeqta publ AB (SPEQT)August 25, 2023 | seekingalpha.comPRXXF Paradox Interactive AB (publ)February 26, 2023 | seekingalpha.comOXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2MMarch 11, 2022 | stockhouse.comOrexo appoints Fredrik Järrsten as new CFONovember 29, 2021 | finanznachrichten.deNotice of extra general meeting in Terranet ABJuly 22, 2021 | investing.comFancy Wood Industries PCL (FANCY)See More Headlines Receive OASM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oasmia Pharmaceutical AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:OASM CUSIPN/A CIK1607245 Webwww.oasmia.com Phone(461) 850-5440FaxN/AEmployees57Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,950,000.00 Net Margins-8,633.64% Pretax MarginN/A Return on Equity-43.94% Return on Assets-28.92% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.73 Sales & Book Value Annual Sales$220,000.00 Price / Sales6.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / Book0.03Miscellaneous Outstanding Shares74,967,000Free FloatN/AMarket Cap$1.50 million OptionableNot Optionable Beta0.96 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesFrançois R. MarteletChief Executive OfficerFredrik JärrstenChief Financial OfficerMikael AspChief Technology OfficerNigel GoodmanDirector-Clinical OperationsCarina EklöwDirector-Global Medical AffairsKey CompetitorsHistogenNASDAQ:HSTOPanbela TherapeuticsNASDAQ:PBLAGRI BioNASDAQ:GRINeuBase TherapeuticsNASDAQ:NBSE180 Life SciencesNASDAQ:ATNFView All Competitors OASM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oasmia Pharmaceutical AB (publ) investors own include G1 Therapeutics (GTHX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Supernus Pharmaceuticals (SUPN), Verastem (VSTM), Akari Therapeutics (AKTX), Nightstar Therapeutics (NITE), Novavax (NVAX) and OpGen (OPGN). This page (NASDAQ:OASM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchGreat Crypto BullWeiss RatingsMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
